Article
Reduction of LOXL2-mediated H3K4 oxidation increases chromatin accessibility and promotes…
medRxiv · 2018 · Cebria-Costa, J. P.; Pascual-Reguant, L.; Gonzalez Perez, A.; Serra-Bardenys, G.; Querol, J.; Cosin, M.; Verde, G.; Aiese Cigliano, R.; Sanseverino, W.; Segura-Bayona, S.; Iturbide, A.; Andreu, D.; Nuciforo, P.; Bernado Morales, C.; Rodilla, V.; Arribas, J.; Yelamos, J.; Garcia de Herreros, A.; Stracker, T. H.; Peiro, S.
Key facts
| Title | Reduction of LOXL2-mediated H3K4 oxidation increases chromatin accessibility and promotes chemosensitivity of triple-negative breast cancer cells |
|---|---|
| First author | Cebria-Costa, J. P.; Pascual-Reguant, L.; Gonzalez Perez, A.; Serra-Bardenys, G.; Querol, J.; Cosin, M.; Verde, G.; Aiese Cigliano, R.; Sanseverino, W.; Segura-Bayona, S.; Iturbide, A.; Andreu, D.; Nuciforo, P.; Bernado Morales, C.; Rodilla, V.; Arribas, J.; Yelamos, J.; Garcia de Herreros, A.; Stracker, T. H.; Peiro, S. |
| Journal | medRxiv |
| Published | Sep 13, 2018 |
| DOI | 10.1101/416495 |
| Devices mentioned | BK110039, DEN000008, K022086, K030528, K031042, K031044, K800781 |
| Product codes mentioned | JCI, KIP, KIT, NDS, NJT, PFT, JIY, KIS, KNK, LCP, PCA |
At a glance
- 1–9 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1